{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:26:08Z","timestamp":1787066768442,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,29]]},"DOI":"10.7759\/cureus.72596","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T03:06:01Z","timestamp":1730171161000},"source":"Crossref","is-referenced-by-count":3,"title":["Vitamin E and Non-alcoholic Fatty Liver Disease: Investigating the Evidence Through a Systematic Review"],"prefix":"10.7759","author":[{"given":"Mahlet","family":"Abera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchith B","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Malireddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruthi","family":"Boddeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khutaija","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehwish","family":"Ansar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iana","family":"Malasevskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng ML","year":"2023","unstructured":"Teng ML, Ng CH, Huang DQ, et al.. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023, 29:S32-42. 10.3350\/cmh.2022.0365","journal-title":"Clin Mol Hepatol"},{"key":"ref2","article-title":"Nonalcoholic fatty liver disease: clinical features and pathogenesis","volume":"2","author":"Basaranoglu M","year":"2006","unstructured":"Basaranoglu M, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease: clinical features and pathogenesis. Gastroenterol Hepatol (N Y). 2006, 2:282-91.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al.. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023, 77:1797-835. 10.1097\/HEP.0000000000000323","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni CA","year":"1999","unstructured":"Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999, 116:1413-9. 10.1016\/s0016-5085(99)70506-8","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes C","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018, 67:123-33. 10.1002\/hep.29466","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43635","article-title":"Vitamin E and pioglitazone: a comprehensive systematic review of their efficacy in non-alcoholic fatty liver disease","volume":"15","author":"Mazhar IJ","year":"2023","unstructured":"Mazhar IJ, Yasir M, Sarfraz S, et al.. Vitamin E and pioglitazone: a comprehensive systematic review of their efficacy in non-alcoholic fatty liver disease. Cureus. 2023, 15:e43635. 10.7759\/cureus.43635","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9018","article-title":"Vitamin E as an adjuvant treatment for non-alcoholic fatty liver disease in adults: a systematic review of randomized controlled trials","volume":"12","author":"Usman M","year":"2020","unstructured":"Usman M, Bakhtawar N. Vitamin E as an adjuvant treatment for non-alcoholic fatty liver disease in adults: a systematic review of randomized controlled trials. Cureus. 2020, 12:e9018. 10.7759\/cureus.9018","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref11","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells GA","year":"2020","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital, Ontario, Canada; 2020."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-020-01131-x","article-title":"Efficacy of combining pentoxiphylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitis-a randomized pilot study","volume":"40","author":"Kedarisetty CK","year":"2021","unstructured":"Kedarisetty CK, Bhardwaj A, Kumar G, Rastogi A, Bihari C, Kumar M, Sarin SK. Efficacy of combining pentoxiphylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitis-a randomized pilot study. Indian J Gastroenterol. 2021, 40:41-9. 10.1007\/s12664-020-01131-x","journal-title":"Indian J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/1319-3767.182451","article-title":"An open-label randomized control study to compare the efficacy of vitamin E versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients","volume":"22","author":"Parikh P","year":"2016","unstructured":"Parikh P, Ingle M, Patel J, Bhate P, Pandey V, Sawant P. An open-label randomized control study to compare the efficacy of vitamin E versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients. Saudi J Gastroenterol. 2016, 22:192-7. 10.4103\/1319-3767.182451","journal-title":"Saudi J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2006.01295.x","article-title":"Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study","volume":"37","author":"Yakaryilmaz F","year":"2007","unstructured":"Yakaryilmaz F, Guliter S, Savas B, et al.. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern Med J. 2007, 37:229-35. 10.1111\/j.1445-5994.2006.01295.x","journal-title":"Intern Med J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal AJ","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, et al.. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010, 362:1675-85. 10.1056\/NEJMoa0907929","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-12-166","article-title":"Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial","volume":"12","author":"Magosso E","year":"2013","unstructured":"Magosso E, Ansari MA, Gopalan Y, et al.. Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial. Nutr J. 2013, 12:166. 10.1186\/1475-2891-12-166","journal-title":"Nutr J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12989","article-title":"Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial","volume":"19","author":"Polyzos SA","year":"2017","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS, Polymerou V, Katsinelos P. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial. Diabetes Obes Metab. 2017, 19:1805-9. 10.1111\/dom.12989","journal-title":"Diabetes Obes Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2018.17297","article-title":"Effects of delta-tocotrienol supplementation on liver enzymes, inflammation, oxidative stress and hepatic steatosis in patients with nonalcoholic fatty liver disease","volume":"29","author":"Pervez MA","year":"2018","unstructured":"Pervez MA, Khan DA, Ijaz A, Khan S. Effects of delta-tocotrienol supplementation on liver enzymes, inflammation, oxidative stress and hepatic steatosis in patients with nonalcoholic fatty liver disease. Turk J Gastroenterol. 2018, 29:170-6. 10.5152\/tjg.2018.17297","journal-title":"Turk J Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril F","year":"2019","unstructured":"Bril F, Biernacki DM, Kalavalapalli S, et al.. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2019, 42:1481-8. 10.2337\/dc19-0167","journal-title":"Diabetes Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001369","article-title":"Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial","volume":"31","author":"Anushiravani A","year":"2019","unstructured":"Anushiravani A, Haddadi N, Pourfarmanbar M, Mohammadkarimi V. Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. Eur J Gastroenterol Hepatol. 2019, 31:613-7. 10.1097\/MEG.0000000000001369","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref21","article-title":"A Study to Evaluate the Safety and Efficacy of Betaine and Vitamin E in Treating Non-alcoholic Fatty Liver Disease (NAFLD) in Adults","author":"Rotman Y","year":"2023","unstructured":"Rotman Y. A Study to Evaluate the Safety and Efficacy of Betaine and Vitamin E in Treating Non-alcoholic Fatty Liver Disease (NAFLD) in Adults. 2023."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202112_27442","article-title":"A randomized controlled trial comparing the effects of vitamin E, ursodeoxycholic acid and pentoxifylline on Egyptian non-alcoholic steatohepatitis patients","volume":"25","author":"Fouda A","year":"2021","unstructured":"Fouda A, Abdelaziz AE, Hussien M, Ali AA, Abdelkawy KS, Elbarbry F. A randomized controlled trial comparing the effects of vitamin E, ursodeoxycholic acid and pentoxifylline on Egyptian non-alcoholic steatohepatitis patients. Eur Rev Med Pharmacol Sci. 2021, 25:7449-59. 10.26355\/eurrev_202112_27442","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2022.102866","article-title":"Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: a randomized double-blind active-controlled trial","volume":"70","author":"Pervez MA","year":"2022","unstructured":"Pervez MA, Khan DA, Mirza SA, Slehria AU, Nisar U, Aamir M. Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: a randomized double-blind active-controlled trial. Complement Ther Med. 2022, 70:102866. 10.1016\/j.ctim.2022.102866","journal-title":"Complement Ther Med"},{"key":"ref24","article-title":"Vitamin E and DHA-EE on NAFLD - randomized, double-blind, placebo-controlled, parallel-group clinical trial (PUVENAFLD)","author":"Chalasani NP","year":"2023","unstructured":"Chalasani NP. Vitamin E and DHA-EE on NAFLD - randomized, double-blind, placebo-controlled, parallel-group clinical trial (PUVENAFLD). 2023."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2015.21.4.379","article-title":"Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: a propensity score-matched cohort study","volume":"21","author":"Kim GH","year":"2015","unstructured":"Kim GH, Chung JW, Lee JH, et al.. Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: a propensity score-matched cohort study. Clin Mol Hepatol. 2015, 21:379-86. 10.3350\/cmh.2015.21.4.379","journal-title":"Clin Mol Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/diseases6040086","article-title":"The role of vitamin E in the treatment of NAFLD","volume":"6","author":"Perumpail BJ","year":"2018","unstructured":"Perumpail BJ, Li AA, John N, et al.. The role of vitamin E in the treatment of NAFLD. Diseases. 2018, 6:86. 10.3390\/diseases6040086","journal-title":"Diseases"},{"key":"ref27","article-title":"Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis","volume":"8","author":"Xu R","year":"2015","unstructured":"Xu R, Tao A, Zhang S, Deng Y, Chen G. Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis. Int J Clin Exp Med. 2015, 8:3924-34.","journal-title":"Int J Clin Exp Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/305756-vitamin-e-and-non-alcoholic-fatty-liver-disease-investigating-the-evidence-through-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T03:06:05Z","timestamp":1730171165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/305756-vitamin-e-and-non-alcoholic-fatty-liver-disease-investigating-the-evidence-through-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.72596","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,29]]}}}